Top

International Ophthalmology

Published in:

Open Access 01-12-2024 | Optic Neuritis | Original Paper

Visualization and analysis of mapping knowledge domains for optic neuritis: a bibliometric research from 2013 to 2022

Authors: Bo Jiang, Nan Hong, Fangkun Zhao, Feng Dong

Published in: International Ophthalmology | Issue 1/2024

Abstract

Purpose

To explore the global research trends, hotspots and frontiers of optic neuritis (ON) over the past decade through qualitative and quantitative analysis of bibliometrics.

Methods

Publications on ON from 2013 to 2022 were retrieved from Web of Science Core Collection (WoSCC). VOSviewer and CiteSpace were mainly used to facilitate bibliometric analysis and visualization.

Results

A total of 3027 papers were retrieved from peer-reviewed publications and the annual research output increased over time. Neurosciences neurology was the most published area. The USA was the most productive and influential country, and in the focus of international cooperation. University College London was the most productive organization and Charite Medical University of Berlin had the largest number of cooperating partners. Paul F contributed the largest number of publications and Wingerchuk DM ranked first among the co-cited authors. Multiple Sclerosis and Related Disorders was the most prolific journal publishing ON research. The most co-cited references mainly focused on the diagnostic criteria for neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). The keywords formed the following four clusters: the pathophysiology of MS-ON; the autoantibody markers and diagnostic criteria of NMOSD-ON and myelin oligodendrocyte glycoprotein associated disorder-ON (MOGAD-ON); the epidemiology and clinical characteristics of ON; and the treatment of ON.

Conclusion

This bibliometrics analysis showed a systematic view of the evolutionary process, research hotspots, and future directions of ON research. It can provide insights for ON research and valuable information for neuro-ophthalmologic specialists to evaluate research policies and promote international cooperation.

Available only for authorised users

Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13:83–99. https://doi.org/10.1016/S1474-4422(13)70259-XCrossRefPubMed

Hickman SJ, Petzold A (2022) Update on optic neuritis: an international view. Neuroophthalmology 46:1–18. https://doi.org/10.1080/01658107.2021.1964541CrossRefPubMed

Petzold A, Fraser CL, Abegg M et al (2022) Diagnosis and classification of optic neuritis. Lancet Neurol 21:1120–1134. https://doi.org/10.1016/S1474-4422(22)00200-9CrossRefPubMed

Thompson AJ, Baranzini SE, Geurts J et al (2018) Multiple sclerosis. Lancet 391:1622–1636. https://doi.org/10.1016/S0140-6736(18)30481-1CrossRefPubMed

Gospe SM 3rd, Chen JJ, Bhatti MT (2021) Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye (Lond) 35:753–768. https://doi.org/10.1038/s41433-020-01334-8CrossRefPubMed

Britze J, Frederiksen JL (2018) Optical coherence tomography in multiple sclerosis. Eye (Lond) 32:884–888. https://doi.org/10.1038/s41433-017-0010-2CrossRefPubMed

Zhao F, Du F, Zhang J et al (2019) Trends in research related to keratoconus from 2009 to 2018: a bibliometric and knowledge mapping analysis. Cornea 38:847–854. https://doi.org/10.1097/ICO.0000000000001984CrossRefPubMedPubMedCentral

Huang Y, Gong Y, Liu Y et al (2022) Global trends and hot topics in electrical stimulation of skeletal muscle research over the past decade: a bibliometric analysis. Front Neurol 13:991099. https://doi.org/10.3389/fneur.2022.991099CrossRefPubMedPubMedCentral

Xu J, Zhao F, Fang J et al (2022) Mapping research trends of chronic ocular graft-versus-host disease from 2009 to 2020: a bibliometric analysis. Int Ophthalmol 42:3963–3976. https://doi.org/10.1007/s10792-022-02380-9CrossRefPubMed

10.

Peng C, Kuang L, Zhao J et al (2022) Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020. J Control Release Off J Control Release Soc 345:625–645. https://doi.org/10.1016/j.jconrel.2022.03.031CrossRef

11.

van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523–538. https://doi.org/10.1007/s11192-009-0146-3CrossRefPubMed

12.

Chen C, Leydesdorff L (2014) Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Am Soc Inf Sci 65:334–351

13.

Lu C, Liu M, Shang W et al (2020) Knowledge mapping of Angelica sinensis (Oliv.) Diels (Danggui) research: a scientometric study. Front Pharmacol 11:294. https://doi.org/10.3389/fphar.2020.00294ADSCrossRefPubMedPubMedCentral

14.

Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474–481. https://doi.org/10.1212/WNL.0000000000000101CrossRefPubMedPubMedCentral

15.

Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189. https://doi.org/10.1212/WNL.0000000000001729CrossRefPubMedPubMedCentral

16.

Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489. https://doi.org/10.1212/01.wnl.0000216139.44259.74CrossRefPubMed

17.

Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed

18.

Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614–625. https://doi.org/10.1056/NEJMoa1900866CrossRefPubMed

19.

Stiebel-Kalish H, Hellmann MA, Mimouni M et al (2019) Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol R Neuroimmunol Neuroinflam 6:e572. https://doi.org/10.1212/NXI.0000000000000572CrossRef

20.

Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. https://doi.org/10.1002/ana.22366CrossRefPubMedPubMedCentral

21.

Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273–1277. https://doi.org/10.1212/WNL.0b013e31826aac4eCrossRefPubMed

22.

Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71:276–283. https://doi.org/10.1001/jamaneurol.2013.5857CrossRefPubMed

23.

Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112. https://doi.org/10.1016/S0140-6736(04)17551-XCrossRefPubMed

24.

Petzold A, Balcer LJ, Calabresi PA et al (2017) Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 16:797–812. https://doi.org/10.1016/S1474-4422(17)30278-8CrossRefPubMed

25.

Puthenparampil M, Federle L, Poggiali D et al (2017) Trans-synaptic degeneration in the optic pathway: a study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. PLoS ONE 12:e0183957. https://doi.org/10.1371/journal.pone.0183957CrossRefPubMedPubMedCentral

26.

Nolan-Kenney RC, Liu M, Akhand O et al (2019) Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: an international study. Ann Neurol 85:618–629. https://doi.org/10.1002/ana.25462CrossRefPubMed

27.

Bennett JL, de Seze J, Lana-Peixoto M et al (2015) Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler 21:678–688. https://doi.org/10.1177/1352458514567216CrossRefPubMedPubMedCentral

28.

Yousefipour G, Hashemzahi Z, Yasemi M et al (2016) Findings of optical coherence tomography of retinal nerve fiber layer in two common types of multiple sclerosis. Acta Med Iran 54:382–390PubMed

29.

Vidal-Jordana A, Pareto D, Cabello S et al (2020) Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability. Eur J Neurol 27:2225–2232. https://doi.org/10.1111/ene.14421CrossRefPubMed

30.

Esen E, Sizmaz S, Balal M et al (2016) Evaluation of the innermost retinal layers and visual evoked potentials in patients with multiple sclerosis. Curr Eye Res 41:1353–1358. https://doi.org/10.3109/02713683.2015.1119283CrossRefPubMed

31.

Uzunkopru C, Yuceyar N, Yilmaz SG et al (2021) Retinal nerve fiber layer thickness correlates with serum and cerebrospinal fluid neurofilament levels and is associated with current disability in multiple sclerosis. Noro psikiyatri arsivi 58:34–40. https://doi.org/10.29399/npa.27355CrossRefPubMedPubMedCentral

32.

Murphy OC, Kalaitzidis G, Vasileiou E et al (2020) Optical coherence tomography and optical coherence tomography angiography findings after optic neuritis in multiple sclerosis. Front Neurol 11:618879. https://doi.org/10.3389/fneur.2020.618879CrossRefPubMedPubMedCentral

33.

Chan JK, Martinez H, de Lapiscina E, Taylor C et al (2020) Long-term stability of neuroaxonal structure in alemtuzumab-treated relapsing-remitting multiple sclerosis patients. J Neuroophthalmol 40:37–43. https://doi.org/10.1097/WNO.0000000000000802CrossRefPubMed

34.

Feucht N, Maier M, Lepennetier G et al (2019) Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Mult Scler 25:224–234. https://doi.org/10.1177/1352458517750009CrossRefPubMed

35.

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477. https://doi.org/10.1084/jem.20050304CrossRefPubMedPubMedCentral

36.

Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. https://doi.org/10.1186/1742-2094-9-14CrossRefPubMedPubMedCentral

37.

Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflam 15:134. https://doi.org/10.1186/s12974-018-1144-2CrossRef

38.

Hoftberger R, Guo Y, Flanagan EP (2020) The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 139:875–892. https://doi.org/10.1007/s00401-020-02132-yCrossRefPubMedPubMedCentral

39.

Hor JY, Asgari N, Nakashima I et al (2020) Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11:501. https://doi.org/10.3389/fneur.2020.00501CrossRefPubMedPubMedCentral

40.

Optic Neuritis Study G (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732. https://doi.org/10.1001/archneur.65.6.727CrossRef

41.

Chen JJ, Flanagan EP, Jitprapaikulsan J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8–15. https://doi.org/10.1016/j.ajo.2018.07.020CrossRefPubMedPubMedCentral

42.

Huda S, Whittam D, Bhojak M et al (2019) Neuromyelitis optica spectrum disorders. Clin Med 19:169–176. https://doi.org/10.7861/clinmedicine.19-2-169CrossRef

43.

Dinoto A, Sechi E, Flanagan EP et al (2022) Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease. Front Neurol 13:866824. https://doi.org/10.3389/fneur.2022.866824CrossRefPubMedPubMedCentral

44.

Liu C, Lu Y, Wang J et al (2021) Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study. J Neurochem 159:913–922. https://doi.org/10.1111/jnc.15478CrossRefPubMed

45.

Jossy A, Jacob N, Sarkar S et al (2022) COVID-19-associated optic neuritis: a case series and review of literature. Indian J Ophthalmol 70:310–316. https://doi.org/10.4103/ijo.IJO_2235_21CrossRefPubMed

46.

Pirani V, Pelliccioni P, Carpene MJ et al (2022) Optic neuritis following COVID-19 vaccination: Do autoimmune diseases play a role? Eur J Ophthalmol. https://doi.org/10.1177/11206721221118736CrossRefPubMedPubMedCentral

47.

Shirah B, Mulla I, Aladdin Y (2022) Optic neuritis following the BNT162b2 mRNA COVID-19 vaccine in a patient with systemic lupus erythematosus uncovering the diagnosis of neuromyelitis optica spectrum disorders. Ocular Immunol Inflam. https://doi.org/10.1080/09273948.2022.2089901CrossRef

48.

Morrow SA, Fraser JA, Day C et al (2018) Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol 75:690–696. https://doi.org/10.1001/jamaneurol.2018.0024CrossRefPubMedPubMedCentral

49.

Petzold A, Braithwaite T, van Oosten BW (2020) Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. J Neurol Neurosurg Psychiatry 91:9–14. https://doi.org/10.1136/jnnp-2019-321653CrossRefPubMed

50.

Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M (2016) Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 22:185–192. https://doi.org/10.1177/1352458515581438CrossRefPubMed

51.

Bonnan M, Valentino R, Debeugny S et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89:346–351. https://doi.org/10.1136/jnnp-2017-316286CrossRefPubMed

52.

Lipphardt M, Muhlhausen J, Kitze B et al (2019) Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. J Clin Apheresis 34:381–391. https://doi.org/10.1002/jca.21686CrossRefPubMed

53.

Faissner S, Nikolayczik J, Chan A et al (2016) Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 9:281–286. https://doi.org/10.1177/1756285616646332CrossRefPubMedPubMedCentral

54.

Tselis A, Perumal J, Caon C et al (2008) Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 15:1163–1167. https://doi.org/10.1111/j.1468-1331.2008.02258.xCrossRefPubMed

55.

Mimura O, Ishikawa H, Kezuka T et al (2021) Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol 65:122–132. https://doi.org/10.1007/s10384-020-00790-9CrossRefPubMed

56.

Song H, Zhou H, Wei S (2022) Update on glial antibody-mediated optic neuritis. Jpn J Ophthalmol. https://doi.org/10.1007/s10384-022-00932-1CrossRefPubMed

57.

Hayward-Koennecke H, Reindl M, Martin R et al (2019) Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology 92:765–767. https://doi.org/10.1212/WNL.0000000000007312CrossRefPubMed

58.

Thakolwiboon S, Zhao-Fleming H, Karukote A et al (2021) Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. Multiple Sclerosis Relat Disord 56:103310. https://doi.org/10.1016/j.msard.2021.103310CrossRef

59.

Redenbaugh V, Flanagan EP (2022) Monoclonal antibody therapies beyond complement for NMOSD and MOGAD. Neurother J Am Soc Exp NeuroTher 19:808–822. https://doi.org/10.1007/s13311-022-01206-xCrossRef

60.

Raftopoulos R, Hickman SJ, Toosy A et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15:259–269. https://doi.org/10.1016/S1474-4422(16)00004-1CrossRefPubMed

61.

Petrillo J, Balcer L, Galetta S et al (2019) Initial impairment and recovery of vision-related functioning in participants with acute optic neuritis from the RENEW trial of opicinumab. J Neuroophthalmol 39:153–160. https://doi.org/10.1097/WNO.0000000000000697CrossRefPubMed

Title: Visualization and analysis of mapping knowledge domains for optic neuritis: a bibliometric research from 2013 to 2022
Authors: Bo Jiang
Nan Hong
Fangkun Zhao
Feng Dong
Publication date: 01-12-2024
Publisher: Springer Netherlands
Keywords: Optic Neuritis
Neuromyelitis Optica Spectrum Disease
Multiple Sclerosis
Published in: International Ophthalmology / Issue 1/2024
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-02948-7

At a glance: The STEP trials

Springer Medicine

Visualization and analysis of mapping knowledge domains for optic neuritis: a bibliometric research from 2013 to 2022

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Pro re nata anti-VEGF treatment in pachychoroid neovasculopathy compared with age-related macular degeneration based on optical coherence tomography

PD protects Müller cells through the SIRT1/NLRP3 inflammasome pathway

Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

Whole-orbit-based multiparametric assessment of disease activity of thyroid eye disease on Dixon MRI

Assessment of the relationship between structural and functional tests in patients with idiopathic intracranial hypertension

Congenital ptosis with aponeurotic maldevelopment: clinical and surgical perspectives